Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712995 | 1.00 | KMT2A (0.75) | KMT2AMAPK1BRD4MAPTSMN1; SMN2 | |
| SCHEMBL2183176 | 1.00 | KMT2A (0.75) | KMT2AMAPK1BRD4MAPTSMN1; SMN2 | |
| SCHEMBL5460103 | 1.00 | KMT2A (0.75) | KMT2AMAPK1BRD4MAPTSMN1; SMN2 | |
| SCHEMBL1713280 | 1.00 | KMT2A (0.75) | KMT2AMAPK1BRD4MAPTSMN1; SMN2 | |
| SCHEMBL1713279 | 1.00 | KMT2A (0.75) | KMT2AMAPK1BRD4MAPTSMN1; SMN2 | |
| SCHEMBL27885819 | 1.00 | KMT2A (0.75) | KMT2AMAPK1BRD4MAPTSMN1; SMN2 | |
| SCHEMBL1712998 | 1.00 | KMT2A (0.75) | KMT2AMAPK1BRD4MAPTSMN1; SMN2 | |
| SCHEMBL14310707 | 0.87 | KMT2A (0.71) | KMT2AMAPK1MAPTSMN1; SMN2HPGD | |
| SCHEMBL739505 | 0.87 | KMT2A (0.71) | KMT2AMAPK1MAPTSMN1; SMN2HPGD | |
| SCHEMBL9428951 | 0.87 | KMT2A (0.71) | KMT2AMAPK1MAPTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| EP-2097400-B1 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| EP-2540715-A1 | Fused substituted aminopyrrolidine derivative | Daiichi Sankyo Company, Limited (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| WO-2008082009-A2 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | KMT2A 2847/4885MAPK1 2614/4885BRD4 102/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | KMT2A 2847/4885MAPK1 2614/4885BRD4 102/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | KMT2A 2847/4885MAPK1 2614/4885BRD4 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.